Both in Biotechnology
Metagenomi Therapeutics vs INmune Bio
Over the past year MGX returned −67.7% and INMB returned −33.6%; their daily moves had a correlation of 0.31.
MGX −67.7% INMB −33.6%Growth of $1, one year, split-adjusted
| Metric | MGX | INMB |
|---|---|---|
| Price | $0.7308 | $1.18 |
| Market cap | $27.6M | $36.4M |
| Today | −7.49% | −11.65% |
| 1 month | −25.8% | −36.8% |
| 6 months | −48.5% | −17.8% |
| Year to date | −54.9% | −24.7% |
| 1 year | −68.1% | −31.7% |
| Revenue growth (YoY) | −103.0% | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 2.0× | — |
| Net cash | $120.7M | $18.4M |
| Dividend yield | — | — |
| Volatility (60d) | 49.8% | 69.5% |
| Short % of float | 5.2% | 11.7% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).